主页 > 医药生命 >

【drug-news】抗抑郁药的作用受患者基因影响(s

Genes Can Impact Depression Treatment

Patients with specific DNA were 40 percent more likely to respond, study found

HealthDay
By Robert Preidt
Wednesday, December 6, 2006

WEDNESDAY, Dec. 6 (HealthDay News) -- U.S. researchers say they've spotted genetic variations that affect how patients respond to antidepressants.

"Medications to treat depression are widely available, but no one treatment works for everyone. Additionally, it can be difficult to predict which patients will experience harmful or unpleasant side effects," Dr. Francis McMahon, chief of Genetic Basis of Mood & Anxiety Disorders at the U.S. National Institute of Mental Health explained in a prepared statement.

"We are seeking to better understand why this is the case and, using genetic markers, develop personalized treatments that give patients the best chance at remission," McMahon said.

For this study, which included more than 1,900 people with major depression, researchers examined the effects that polymorphisms (common differences in DNA sequences) of 68 genes had on depression treatment effectiveness and side effects. The patients were treated with the antidepressant citalopram for at least six weeks.

Polymorphisms in a gene that regulated serotonin were associated with treatment outcome, the team found. People who carried two copies of the polymorphism were 18 percent more likely to respond to antidepressant treatment than patients who didn't have two copies, McMahon said.

Polymorphisms in two other genes -- a protein involved in neurogenesis and a receptor for the brain chemical glutamate -- also influenced the effectiveness of the antidepressant, the study said.

Patients with all three response-associated polymorphisms were 40 percent more likely to respond to treatment than patients with none of the polymorphisms.

The findings were slated for presentation Wednesday at the annual meeting of the American College of Neuropsychopharmacology.

"Ultimately, our goal is to put together a panel of genetic markers that can guide treatment decisions and help doctors choose an antidepressant that will work best for an individual patient," McMahon said.

http://www.nlm.nih.gov/medlineplus/news/fullstory_42266.html 本人已认领该文编译,48小时后若未提交译文,请其他战友自由认领。 Genes Can Impact Depression Treatment
基因可能会影响抑郁症的治疗
Patients with specific DNA were 40 percent more likely to respond, study found 研究发现,携带特定DNA的患者40%更易于对治疗作出反应。

HealthDay
By Robert Preidt
Wednesday, December 6, 2006
2006年12月6日、星期三,
WEDNESDAY, Dec. 6 (HealthDay News) -- U.S. researchers say they've spotted genetic variations that affect how patients respond to antidepressants.美国研究人员称,他们已经发现一些遗传变异,该变异可影响抗抑郁药对患者的效果。

"Medications to treat depression are widely available, but no one treatment works for everyone. Additionally, it can be difficult to predict which patients will experience harmful or unpleasant side effects," Dr. Francis McMahon, chief of Genetic Basis of Mood & Anxiety Disorders at the U.S. National Institute of Mental Health explained in a prepared statement. 美国国家精神健康协会情绪和焦虑障碍遗传学机理的负责人,Francis McMahon教授,在拟好的报告中声称,虽然抗抑郁症的药物已广泛应用,但还没有一种药物是万能的。此外,目前还很难预测哪些患者会出现有害或难受的副作用。

"We are seeking to better understand why this is the case and, using genetic markers, develop personalized treatments that give patients the best chance at remission," McMahon said. McMahon说,我们就是要更好得去理解情况为什么是这样的,并且通过应用遗传标记,实现个体化治疗,即给予患者最佳治疗方案。

For this study, which included more than 1,900 people with major depression, researchers examined the effects that polymorphisms (common differences in DNA sequences) of 68 genes had on depression treatment effectiveness and side effects. The patients were treated with the antidepressant citalopram for at least six weeks.该研究纳入1900多名患有严重抑郁症的病人,研究者调查了68个基因的多态性(是DNA序列常见的变异)对于抗抑郁疗效和副作用的影响。患者使用抗抑郁药物、西酞普兰至少六周。

Polymorphisms in a gene that regulated serotonin were associated with treatment outcome, the team found. People who carried two copies of the polymorphism were 18 percent more likely to respond to antidepressant treatment than patients who didn't have two copies, McMahon said.研究小组发现,负责调节5-羟色氨酸基因的多态性与疗效相关。携带两个拷贝多态性者较之没有携带双拷贝者对抗抑郁药的反应性高18%。

阅读本文的人还阅读:

【编译】碳水化合物消费

【medical-news】NICE新指南

[JAMA---NUEROLOGY编译]线粒体

【bio-news】基因修饰细胞

【medical-news】家族甲状腺

作者:admin@医学,生命科学    2011-05-23 05:14
医学,生命科学网